tetano
Editor, Senior Moderator
Sci Rep
. 2022 Jun 1;12(1):9147.
doi: 10.1038/s41598-022-12834-w.
Low SARS-CoV-2 antibody titers may be associated with poor clinical outcomes for patients with severe COVID-19
Mumon Takita[SUP] 1 [/SUP], Toru Yoshida[SUP] 1 [/SUP], Tomoya Tsuchida[SUP] 2 [/SUP], Yu Nakagama[SUP] 3 [/SUP], Yasutoshi Kido[SUP] 3 [/SUP], Shotaro Suzuki[SUP] 4 [/SUP], Mitsuru Imamura[SUP] 4 [/SUP], Kimito Kawahata[SUP] 4 [/SUP], Goji Shimizu[SUP] 1 [/SUP], Hideki Yoshida[SUP] 1 [/SUP], Daiki Morikawa[SUP] 1 [/SUP], Takeshi Kawaguchi[SUP] 1 [/SUP], Shuichi Fujii[SUP] 1 [/SUP], Jumpei Tsukuda[SUP] 1 [/SUP], Takako Motohashi[SUP] 5 [/SUP], Shigeki Fujitani[SUP] 6 [/SUP]
Affiliations
Abstract
Recently, immune response to coronavirus disease (COVID-19) has attracted attention where an association between higher antibody titer and worsening disease severity has been reported. However, our experiences with severe COVID-19 patients with low antibody titers led to hypothesizing that suppressed humoral immune response may be associated with poorer prognosis in severe COVID19. In this study, antibody titers in severe COVID19 patients were measured at 7, 10, 12, and 14 days after onset. Patients were divided into survivors and non-survivors. SARS-CoV-2 IgM in survivors and non-survivors were 0.06 AU and 0.02 AU (P = 0.048) at 10 days, 0.1 AU and 0.03 AU (P = 0.02) at 12 days, and 0.17 AU and 0.06 AU (P = 0.02) at 14 days. IgG in survivors and non-survivors were 0.01 AU and 0.01 AU (P = 0.04) at 7 days, 0.42 AU and 0.01 AU (P = 0.04) at 12 days, and 0.42 AU and 0.01 AU (P = 0.02) at 14 days. Multivariate analysis showed better survival among patients with IgM positivity at 12 days (P = 0.04), IgG positivity at 12 days (P = 0.04), IgM positivity at 14 days (P = 0.008), and IgG positivity at 14 days (P = 0.005). In severe COVID-19, low antibody titers on days 12 and 14 after onset were associated with poorer prognosis.
. 2022 Jun 1;12(1):9147.
doi: 10.1038/s41598-022-12834-w.
Low SARS-CoV-2 antibody titers may be associated with poor clinical outcomes for patients with severe COVID-19
Mumon Takita[SUP] 1 [/SUP], Toru Yoshida[SUP] 1 [/SUP], Tomoya Tsuchida[SUP] 2 [/SUP], Yu Nakagama[SUP] 3 [/SUP], Yasutoshi Kido[SUP] 3 [/SUP], Shotaro Suzuki[SUP] 4 [/SUP], Mitsuru Imamura[SUP] 4 [/SUP], Kimito Kawahata[SUP] 4 [/SUP], Goji Shimizu[SUP] 1 [/SUP], Hideki Yoshida[SUP] 1 [/SUP], Daiki Morikawa[SUP] 1 [/SUP], Takeshi Kawaguchi[SUP] 1 [/SUP], Shuichi Fujii[SUP] 1 [/SUP], Jumpei Tsukuda[SUP] 1 [/SUP], Takako Motohashi[SUP] 5 [/SUP], Shigeki Fujitani[SUP] 6 [/SUP]
Affiliations
- PMID: 35650227
- DOI: 10.1038/s41598-022-12834-w
Abstract
Recently, immune response to coronavirus disease (COVID-19) has attracted attention where an association between higher antibody titer and worsening disease severity has been reported. However, our experiences with severe COVID-19 patients with low antibody titers led to hypothesizing that suppressed humoral immune response may be associated with poorer prognosis in severe COVID19. In this study, antibody titers in severe COVID19 patients were measured at 7, 10, 12, and 14 days after onset. Patients were divided into survivors and non-survivors. SARS-CoV-2 IgM in survivors and non-survivors were 0.06 AU and 0.02 AU (P = 0.048) at 10 days, 0.1 AU and 0.03 AU (P = 0.02) at 12 days, and 0.17 AU and 0.06 AU (P = 0.02) at 14 days. IgG in survivors and non-survivors were 0.01 AU and 0.01 AU (P = 0.04) at 7 days, 0.42 AU and 0.01 AU (P = 0.04) at 12 days, and 0.42 AU and 0.01 AU (P = 0.02) at 14 days. Multivariate analysis showed better survival among patients with IgM positivity at 12 days (P = 0.04), IgG positivity at 12 days (P = 0.04), IgM positivity at 14 days (P = 0.008), and IgG positivity at 14 days (P = 0.005). In severe COVID-19, low antibody titers on days 12 and 14 after onset were associated with poorer prognosis.